Patent details

301023 Product Name: Ravulizumab

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic Information

Publication number:
301023
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP2235059
Status:
Refused Art. 10 of the EC Regulations
Application number:
301023
Procedural language:
Dutch
First Applicant Residence Country:
United States of America (US)

Marketing Authorization

Marketing Authorization Number:
EU/1/19/1371
Marketing Authorization Type:
EEA
Marketing Authorization Date:
05/07/2019
Marketing Authorization Country:
European Union (EU)

Dates

Filing date:
20/12/2019
First Marketing Authorization date:
05/07/2019
Grant date:
Activation date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
24/12/2019
SPC/SPC Extension Expiration Date:
Lapsed By Expiration Date:
Withdrawal date:
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:
21/10/2020

Applicant/holder

From:
20/12/2019
 
 

 

Name:
Xencor, Inc.
Address:
111 W. Lemon Avenue, MONROVIA, CA 91016, United States of America (US)

Agent

Name:
ir. M.F.J.M. Ketelaars c.s.
From:
20/12/2019
Address:
NLO Postbus 29720, 2502 LS, Den Haag, Netherlands (NL)
To:

Publication

Bulletin

1

Bulletin Heading:
VRV
Journal edition number:
43/20
Publication date:
21/10/2020
Description:
Lapse or annulment

2

Bulletin Heading:
SPC
Journal edition number:
53/19
Publication date:
01/01/2020
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
Filing date Document type Document Description Number of pages File Type
21/10/2020 Outgoing Correspondence Decision refusal 3 PDF /0/2/9/7/9/0800497920/docs/301023_6_373556l527a.pdf
07/08/2020 Outgoing Correspondence Letter to applicant 1 PDF /0/2/9/7/9/0800497920/docs/301023_7_359167l173.pdf
04/08/2020 SPC Documents Accompanying letter SPC 1 PDF /0/2/9/7/9/0800497920/docs/301023_5_supplprotectioncertificate20200805085308361.pdf
07/05/2020 Outgoing Correspondence Letter to applicant 3 PDF /0/2/9/7/9/0800497920/docs/301023_10_342938l173.pdf
08/01/2020 SPC Documents Accompanying letter SPC 3 PDF /0/2/9/7/9/0800497920/docs/301023_15_supplprotectioncertificate20200110103406603.pdf
27/12/2019 Outgoing Correspondence Confirmation receipt request 1 PDF /0/2/9/7/9/0800497920/docs/301023_8_317748l174.pdf
20/12/2019 SPC Documents Annex SPC 2 PDF /0/2/9/7/9/0800497920/docs/301023_0_supplprotectioncertificate20191224120155615.pdf
20/12/2019 SPC Documents Annex SPC 5 PDF /0/2/9/7/9/0800497920/docs/301023_1_supplprotectioncertificate20191224120155523.pdf
20/12/2019 SPC Documents Annex SPC 14 PDF /0/2/9/7/9/0800497920/docs/301023_2_supplprotectioncertificate20191224120155571.pdf
20/12/2019 SPC Documents Summary of the characteristics of the product 15 PDF /0/2/9/7/9/0800497920/docs/301023_3_supplprotectioncertificate20191224120155472.pdf
20/12/2019 Application Form First filed application form 2 PDF /0/2/9/7/9/0800497920/docs/301023_4_applicationform20191224114545041.pdf
20/12/2019 Incoming Correspondence Paper Other 143 PDF /0/2/9/7/9/0800497920/docs/301023_9_incomingcorrespondencepaper20200106103821613.pdf
20/12/2019 SPC Documents Marketing Authorization SPC 3 PDF /0/2/9/7/9/0800497920/docs/301023_11_supplprotectioncertificate20191224114545489.pdf
20/12/2019 Incoming Correspondence Paper Other 19 PDF /0/2/9/7/9/0800497920/docs/301023_12_incomingcorrespondencepaper20200106104238050.pdf
20/12/2019 Incoming Correspondence Paper Other 15 PDF /0/2/9/7/9/0800497920/docs/301023_13_incomingcorrespondencepaper20200106104531861.pdf
20/12/2019 Incoming Correspondence Paper Other 128 PDF /0/2/9/7/9/0800497920/docs/301023_14_incomingcorrespondencepaper20200106102258438.pdf